Literature DB >> 16740631

Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences.

Mekdes Debela1, Viktor Magdolen, Norman Schechter, Martina Valachova, Friedrich Lottspeich, Charles S Craik, Youngchool Choe, Wolfram Bode, Peter Goettig.   

Abstract

Human tissue kallikreins (hKs) form a family of 15 closely related (chymo)trypsin-like serine proteinases. These tissue kallikreins are expressed in a wide range of tissues including the central nervous system, the salivary gland, and endocrine-regulated tissues, such as prostate, breast, or testis, and may have diverse physiological functions. For several tissue kallikreins, a clear correlation has been established between expression and different types of cancer. For example, the prostate-specific antigen (PSA or hK3) serves as tumor marker and is used to monitor therapy response. Using a novel strategy, we have cloned, expressed in Escherichia coli or in insect cells, refolded, activated, and purified the seven human tissue kallikreins hK3/PSA, hK4, hK5, hK6, hK7, hK10, and hK11. Moreover, we have determined their extended substrate specificity for the nonprime side using a positional scanning combinatorial library of tetrapeptide substrates. hK3/PSA and hK7 exhibited a chymotrypsin-like specificity preferring large hydrophobic or polar residues at the P1 position. In contrast, hK4, hK5, and less stringent hK6 displayed a trypsin-like specificity with strong preference for P1-Arg, whereas hK10 and hK11 showed an ambivalent specificity, accepting both basic and large aliphatic P1 residues. The extended substrate specificity profiles are in good agreement with known substrate cleavage sites but also in accord with experimentally solved (hK4, hK6, and hK7) or modeled structures. The specificity profiles may lead to a better understanding of human tissue kallikrein functions and assist in identifying their physiological protein substrates as well as in designing more selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740631     DOI: 10.1074/jbc.M602372200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

2.  Crystallization and preliminary crystallographic studies of human kallikrein 7, a serine protease of the multigene kallikrein family.

Authors:  Israel S Fernández; Ludger Ständker; Wolf Georg Forssmann; Guillermo Giménez-Gallego; Antonio Romero
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-07-07

3.  LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Authors:  Celine Deraison; Chrystelle Bonnart; Frederic Lopez; Celine Besson; Ross Robinson; Arumugam Jayakumar; Fredrik Wagberg; Maria Brattsand; Jean Pierre Hachem; Goran Leonardsson; Alain Hovnanian
Journal:  Mol Biol Cell       Date:  2007-06-27       Impact factor: 4.138

4.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

Review 5.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

6.  Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

Review 7.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

8.  Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Authors:  Lakmali Munasinghage Silva; Thomas Kryza; Thomas Stoll; Christine Hoogland; Ying Dong; Carson Ryan Stephens; Marcus Lachlan Hastie; Viktor Magdolen; Oded Kleifeld; Jeffrey John Gorman; Judith Ann Clements
Journal:  Mol Cell Proteomics       Date:  2019-01-31       Impact factor: 5.911

9.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

10.  Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3.

Authors:  Shoba Subramanian; Markus Hardt; Youngchool Choe; Richard K Niles; Eric B Johansen; Jennifer Legac; Jiri Gut; Iain D Kerr; Charles S Craik; Philip J Rosenthal
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.